Compare NetEase Inc (NTES) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs TG Therapeutics Inc — how do they compare? NetEase Inc trades at $122.66 (market cap $82.75B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: NetEase Inc is far larger — about 10.8× TG Therapeutics Inc's market cap, and NetEase Inc pays a 2.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NTES | TGTX | |
|---|---|---|
Market Cap | $82.75B | $7.64B |
Sector | Media | Health |
52-Week High | $159.34 | $59.06 |
52-Week Low | $109.26 | $26.94 |
Enterprise Value | $59.05B | $7.84B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $124.08, down 6.99% over the past 24 hours, with a P/E ratio of 16.31 and strong profitability metrics including a 29.84% net income margin. Recent earnings show mixed results with a Q1 2026 beat but Q3 and Q4 2025 misses. Technical indicators suggest a bullish trend with support at $126 and resistance at $129. The company maintains robust cash flow from operations of $50.74 billion in 2025 and recently announced a $0.72 dividend for H1 2026.
Outlook remains positive with 82% analyst buy ratings and a projected 34.7% upside potential. Key opportunities include international expansion and strong free cash flow generation, while risks involve competitive pressures in gaming and regulatory uncertainties in China. Revenue growth is steady, reaching $112.63 billion in 2025, supporting a solid fundamental base for long-term investors.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
